HCWB (23) SILO (18) REVB (36) DCOY (31) ⌘ Pro Terminal →

Aptevo Therapeutics Inc. (APVO) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell APVO stock right now?

Aptevo Therapeutics Inc. (APVO) currently earns a Roarable Rating of D- (Sell — SELL) with 35/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is APVO's 12-month price target and RQD AI Jury consensus?

APVO's 12-month base price target is $1.2 (range $0.94 to $29.48), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.34 -1.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.33

Aptevo Therapeutics Inc. (APVO) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APVO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Aptevo Therapeutics Inc. (NASDAQ: APVO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.34 (-1.47% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APVO ranks #615 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APVO compare to HCWB and SILO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APVO carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCWB (HCW Biologics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and SILO (Silo Pharma Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, APVO leads on earnings multiple (N/A) while APVO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APVO?

▼

Per APVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671584), Aptevo Therapeutics Inc. generated $0 in revenue, -$26.0M in net income, and -$25.6M in free cash flow against $27.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.33 (-0.45%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APVO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY APVO SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.73-6.4% Next Q

Q2 (-2Q)

Grade D$1.62-21% Next Q

Q3 (-1Q)

Grade E$1.28+4.7% Next Q

Current

Grade D-$1.34-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APVO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APVO currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.81) and Max Pain ($1.41) forces dealer call-delta covering toward $29.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APVO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

2830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.34H: $28

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on APVO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like APVO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APVO)

✓Walkthrough of APVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.41%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.36H $1.36L $1.34C $1.34VOL 28.7K

RES: $3.46SUP: $1.23SMA50: $1.81SMA200: $4.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APVO Butterfly Map → + Track APVO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APVO)

Health Care Rank #615 of 1016 ⚔️ HCWB vs APVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APVO vs. HCWB, SILO, REVB, DCOY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aptevo Therapeutics Inc. (APVO) ranks #615 by composite RQD confidence (35/100, grade D-) and #988 by equity capitalization ($2.4M). Within this direct 5-issuer industry benchmark cohort, APVO leads on earnings valuation at N/A trailing P/E, while APVO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. REVB currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with APVO at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APVO ACTIVE Aptevo Therapeutics Inc.	D-	35/100	—	—	-35.0%	-1.47%	$2.4M	Benchmark Subject
HCWB HCW Biologics Inc.	E	23/100	—	20.0%	-35.0%	-6.78%	$2.5M	/hcwb-vs-apvo →
SILO Silo Pharma Inc.	E	18/100	—	38.6%	-35.0%	-1.60%	$2.3M	/silo-vs-apvo →
REVB Revelation Biosciences Inc.	D-	36/100	—	—	-35.0%	+7.47%	$2.3M	/revb-vs-apvo →
DCOY Decoy Therapeutics Inc.	E	31/100	—	—	-35.0%	-13.01%	$2.6M	/dcoy-vs-apvo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671584

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aptevo Therapeutics Inc. (APVO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.0M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-7.6% YoY). On the balance sheet, APVO closed FY2025 with $27.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.0M	-$25.6M	-$25.6M	$27.2M	—
FY2024 (FY)	2024-12-31	$0	-$24.1M	-$23.8M	-$23.8M	$15.6M	—
FY2023 (FY)	2023-12-31	$0	-$17.4M	-$11.7M	-$11.7M	—	—

3. APVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does APVO compare to HCWB and SILO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for APVO?

Where is APVO trading relative to its 50-day, 200-day, and 52-week technical levels?

APVO last traded at $1.34 (-1.47% on volume of 28,696 shares), positioning the stock -25.97% below its 50-day simple moving average ($1.81) and -68.76% below its 200-day simple moving average ($4.29). Across its 52-week range of $1.25 to $28.08, APVO sits at the 0.3% percentile with a 14-day RSI of 28.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.17 to $1.51).

APVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell APVO stock right now?

Aptevo Therapeutics Inc. (APVO) currently earns a Roarable Rating of D- (Sell — SELL) with 35/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is APVO's 12-month price target and RQD AI Jury consensus?

APVO's 12-month base price target is $1.2 (range $0.94 to $29.48), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: APVO RQD Cockpit APVO 12M Forecast APVO Earnings & Move APVO Dividends & DRIP APVO Insiders & 13F APVO Whale Options APVO Profit Sankey APVO News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

APVO — Aptevo Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, APVO scores 35 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental Cash Engine (7 / 20): Per the RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this indicates the business is not currently generating returns on capital or free cash flow to support valuation on earnings or cash-flow grounds.
Whale 13F Flow (3 / 20): Per the RQD rating, institutional accumulation and options positioning score low. Investors should note the absence of visible institutional sponsorship in the supplied data.
Insider Conviction (5 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow score low, offering limited insider-alignment signal.
Macro Regime Fit (10 / 20): Per the RQD rating, beta is 1.0 and sector sensitivity is assessed at mid-range. Market-wide moves would be expected to transmit to the stock at roughly full magnitude.
Forensic Balance Sheet (10 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the Altman figure warrants caution regarding financial distress risk.

Taken together, the rating points to elevated risk: negative returns on capital, no free-cash-flow yield, weak institutional and insider signals, and a weak Piotroski profile. The upside case rests on factors outside the financial pillars (such as the pipeline news flow described below), which the rating does not quantify as strengths. Valuation cannot be assessed on earnings multiples because P/E and EPS are not available in source data.

Business

Aptevo Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe specific products, customers, or revenue model. Reported revenue for FY 2025, FY 2024, and FY 2023 is $0.0M in each period, per the SEC financials, indicating no reported revenue in the supplied periods. How the company generates or intends to generate income is not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-26.3M	$-26.0M	N/A	$-25.6M	$21.6M	N/A
FY 2024	$0.0M	$-24.6M	$-24.1M	N/A	$-23.8M	$8.7M	N/A
FY 2023	$0.0M	$-28.9M	$-17.4M	N/A	$-11.7M	N/A	N/A

Per the SEC financials, the company reported operating losses and negative free cash flow in each period shown, with net income also negative. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the SEC financials, reported cash rose from $8.7M in FY 2024 to $21.6M in FY 2025, while debt is listed as N/A in each period.

Recent Catalysts & News Wire Analysis

Financing (YELLOW): Per the news wire, Aptevo filed a prospectus supplement for an ATM offering of up to $2.31 Million, reported through TradingView and Stock Titan. An at-the-market offering signals potential share issuance, which can dilute existing holders.
Risk Watch (RED): Per the news wire, a kalkine.ca report describes the stock dropping 6% pre-market despite what it characterizes as strong leukemia data. This item is flagged RED as a risk-watch item.
Earnings Item (YELLOW): Per the news wire, a TradingView item references a Q3'26 earnings revenue estimate of 0 USD.
Price Action (YELLOW): Per the news wire, a Total Put Call item reports shares slipping to $1.79, testing the lower end of a recent range. The current price in market data is 1.36.
Clinical Commentary (YELLOW): Per the news wire, a Stock Titan item references a figure of 10 of 47 newly diagnosed blood cancer patients reaching a donor stem cell transplant, framed as a possible chance of cure.

Per the Butterfly Supply-Chain Graph, the supply_chain value is NONE, and no butterfly links or proprietary signals are present.

Open Questions

What products or pipeline candidates generate or are expected to generate revenue, given zero reported revenue in each supplied period?
What is the size and timing of the ATM offering relative to the current $2.5M market capitalization and reported cash of $21.6M?
What is the company's debt position, since debt is listed as N/A in every supplied period?
What are the reported EPS and valuation multiples, given that P/E, EPS, and EV/EBITDA are unavailable?
What clinical results underlie the leukemia data referenced in the news wire, and how do they relate to the reported 52-week range of $1.25 - $28.44?

APVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aptevo Therapeutics Inc. (APVO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APVO Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 18h ago

Aptevo Therapeutics Files Prospectus Supplement for Up to $2.31 Million ATM Offering

TradingView report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 21h ago

Up to $2.31M in stock may be sold through Roth by Aptevo Therapeutics (APVO).

Stock Titan report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 1d ago

Aptevo Therapeutics (NASDAQ:APVO) Penny Stock Drops 6% Pre-Market Despite Strong Leukemia Data

kalkine.ca report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

APVO Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Aptevo Therapeutics (APVO) Slips to $1.79 as Shares Test Lower End of Recent Range - Total Put Call

https://www.siam.in/ report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

10 of 47 newly diagnosed blood cancer patients reached a donor stem cell transplant. It may offer a chance of cure.

Stock Titan report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Aptevo Therapeutics Reveals 10 Newly Diagnosed AML Patients Progress to Stem Cell Transplant After Mipletamig Combo Therapy

Kalkine Media report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Aptevo Therapeutics Inc. (APVO) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Aptevo Therapeutics Inc. (APVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APVO Bull vs. Bear Conversation Board — What's Your Call at $1.34?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APVO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.20 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is APVO (D- • RQD 35/100) a Buy at $1.36?

Welcome to the APVO (Aptevo Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.02 (-25.0%)

Spot @ $1.36

Pump the brakes on APVO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on APVO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aptevo Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.67 (+22.8%)

Spot @ $1.36

APVO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on APVO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.36 (52-wk range $1.25 - $28.44), any beat on forward guidance forces shorts and underweight funds to chase.